NEW ALBANY — Baptist Health Floyd recently completed its 500th Watchman procedure. The Watchman device is an alternative to ...
Valencia Technologies develops solutions for treating bladder dysfunction. Its FDA-approved eCoin implantable tibial nerve ...
A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...
Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
Investor's Business Daily on MSN
Boston Scientific just took a 9% header. Why analysts are still bullish
Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.
Boston Scientific (BSX) stock plummeted 8% after Raymond James downgraded the company and lowered its price target to $88 on slowing growth in key segments.
The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and efficacy goals in the closely watched CHAMPION-AF study.
In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...
Boston Scientific Corp’s stock recently traded at $65.26, hovering near its 52-week low of $67.56, underscoring a challenging year for the medical device company with a market c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results